The abstract is read at the publisher; the summary is JClub's.
Targeting the hyaluronic acid–CD44 signaling axis is a promising strategy to address tumor progression and therapeutic failure in hepatocellular carcinoma.
- Why it matters: HCC has rising incidence and limited long-term survival, with frequent drug resistance that persists despite systemic therapies. The HA–CD44 interaction in the tumor microenvironment is linked to progression and treatment failure, creating a need for new resistance-focused approaches.
- What they did: This review summarizes potential interventions, including blocking CD44, inhibiting HA synthesis, enzymatically degrading HA, and using HA-based nanocarriers for selective drug delivery, alone or alongside existing treatments. It also discusses how HA–CD44 biology could guide profiling for more personalized care.
- The result: Leveraging HA–CD44 biology may refine patient profiling and support development of more personalized treatments, with the goal of improving outcomes for HCC patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.